HLA B-27 QUALITATIVE PCR

HLA B-27 Qualitative PCR is an advanced molecular diagnostic test used to detect the presence of the HLA-B27 genetic marker in an individual's DNA. The test utilizes Polymerase Chain Reaction (PCR) technology to accurately identify the HLA-B27 gene, which is strongly associated with certain autoimmune and inflammatory disorders, particularly ankylosing spondylitis and related spondyloarthropathies.

HLA-B27 is a genetic marker found on the surface of white blood cells and plays an important role in immune system regulation. Although not everyone with HLA-B27 develops disease, its presence significantly increases the likelihood of certain inflammatory joint and autoimmune conditions. The test helps physicians support diagnosis and clinical evaluation when symptoms suggest these disorders.

Benefits of the Test

• Accurately detects the HLA-B27 genetic marker.
• Supports diagnosis of ankylosing spondylitis.
• Assists in evaluation of inflammatory arthritis.
• Provides reliable molecular genetic results.
• Supports early clinical assessment and management.
• Useful in patients with chronic back pain and joint inflammation.
• Helps identify genetic predisposition to certain autoimmune conditions.
• Assists rheumatologists in treatment planning.

Why Doctors Recommend This Test

Doctors recommend HLA-B27 Qualitative PCR testing for patients with chronic inflammatory back pain, suspected ankylosing spondylitis, reactive arthritis, psoriatic arthritis, inflammatory bowel disease-associated arthritis, unexplained joint inflammation, or recurrent uveitis.

The test provides valuable genetic information that supports diagnosis and helps clinicians evaluate the likelihood of HLA-B27-associated disorders.

Preparation Before Test

• No fasting is required.
• A blood sample is collected for genetic analysis.
• No special dietary restrictions are necessary.
• Inform your doctor about relevant medical history.
• Follow all sample collection instructions carefully.
• Ensure timely specimen submission to the laboratory.

Normal Reporting Time

Most HLA B-27 Qualitative PCR reports at Focus Diagnostics are available within 2–3 hours for specimen processing and molecular workflow initiation. Final genetic analysis, validation, and reporting are generally completed within a few working days depending on laboratory protocols and quality assurance procedures.

Who Should Take This Test?

This test may be recommended for:

• Patients with suspected ankylosing spondylitis.
• Individuals with chronic inflammatory back pain.
• People with unexplained joint stiffness and swelling.
• Patients with reactive arthritis.
• Individuals with psoriatic arthritis.
• Patients with recurrent uveitis.
• People with inflammatory bowel disease-associated arthritis.
• Individuals requiring genetic evaluation for autoimmune disorders.

Detailed Information

Human Leukocyte Antigen B27 (HLA-B27) is a genetic marker belonging to the major histocompatibility complex (MHC) family. It plays an important role in immune system function by helping the body distinguish between its own cells and foreign substances. Certain variations of the HLA-B27 gene have been strongly linked to autoimmune and inflammatory diseases.

The strongest association is seen with ankylosing spondylitis, a chronic inflammatory disease that primarily affects the spine and sacroiliac joints. Many patients diagnosed with ankylosing spondylitis are HLA-B27 positive. However, the presence of HLA-B27 alone does not confirm disease, as many healthy individuals may also carry the marker without developing symptoms.

HLA-B27 testing is frequently used as part of a comprehensive evaluation for spondyloarthropathies, including reactive arthritis, psoriatic arthritis, enteropathic arthritis, and certain forms of inflammatory eye disease such as acute anterior uveitis.

Qualitative PCR testing analyzes the patient's DNA to determine whether the HLA-B27 gene is present or absent. Because genetic markers remain stable throughout life, the test only needs to be performed once in most individuals.

The results help physicians interpret symptoms, clinical findings, imaging studies, and laboratory investigations more accurately. A positive result may support the diagnosis of HLA-B27-associated conditions when consistent symptoms are present.

Results should always be interpreted alongside clinical evaluation, radiological findings, inflammatory markers, and rheumatology assessment. The test is a supportive diagnostic tool and should not be used as the sole basis for diagnosis.

At Focus Diagnostics, HLA B-27 Qualitative PCR testing is performed using advanced molecular diagnostic platforms, validated genetic testing methodologies, and stringent quality assurance standards to provide accurate, reliable, and clinically meaningful genetic results.